Recalcitrant Cancer Research Act of 2012

3.0.0 3566 2020-02-10T17:00:04Z 2020-02-10T17:00:04Z Senate S S 2012-09-19 112 sshr00 Health, Education, Labor, and Pensions Committee Senate Standing Reported original measure 2012-09-19T20:04:12Z Recalcitrant Cancer Research Act of 2012 112 733 HR 2012-09-20 Received in the Senate. Related bill CRS Recalcitrant Cancer Research Act of 2012 112 3560 S 2012-09-19 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Identical bill CRS 2012-09-19 Senate Placed on Senate Legislative Calendar under General Orders. Calendar No. 521. Calendars 2012-09-19 sshr00 Health, Education, Labor, and Pensions Committee Senate Committee on Health, Education, Labor, and Pensions. Original measure reported to Senate by Senator Harkin. Without written report. Committee 2012-09-19 Committee on Health, Education, Labor, and Pensions. Original measure reported to Senate by Senator Harkin. Without written report. Committee 14000 9 Library of Congress sshr00 Health, Education, Labor, and Pensions Committee 2012-09-19 Introduced in Senate IntroReferral 10000 9 Library of Congress H000206 Sen. Harkin, Tom [D-IA] THOMAS HARKIN D IA RICHARD N Health Cancer Congressional oversight Department of Health and Human Services Health information and medical records Health programs administration and funding Health promotion and preventive care Medical research National Institutes of Health (NIH) Research administration and funding Health

00 2012-09-19 Introduced in Senate 2012-10-15T21:35:41Z Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings, identification of promising scientific advances, a description of the availability of qualified scientific researchers, and the identification of resources available to facilitate research; (2) identification of research questions that have not been adequately addressed; and (3) recommendations for actions to advance research and for appropriate benchmarks to measure progress on achieving such actions. Requires the Director to develop the framework within 18 months and review and update it every 5 years.

Requires the Director to identify within 6 months 2 or more recalcitrant cancers that have a 5-year relative survival rate of less than 20%, and are estimated to cause the death of at least 30,000 individuals in the United States per year. Authorizes the Director to identify additional such cancers and to consider additional metrics of progress (such as incidence and mortality rates) against such cancer.

Requires the Director to convene a working group for each identified cancer to provide expertise on, and assist in developing, a scientific framework under this Act.

Requires the Director to consider each relevant scientific framework developed under this Act when making recommendations for exception funding for grant applications.

]]>

80 2012-09-19 Reported to Senate without amendment 2012-11-05T16:59:43Z (This measure has not been amended since it was introduced. The summary of that version is repeated here.)

Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings, identification of promising scientific advances, a description of the availability of qualified scientific researchers, and the identification of resources available to facilitate research; (2) identification of research questions that have not been adequately addressed; and (3) recommendations for actions to advance research and for appropriate benchmarks to measure progress on achieving such actions. Requires the Director to develop the framework within 18 months and review and update it every 5 years.

Requires the Director to convene a working group for each identified cancer to provide expertise on, and assist in developing, a scientific framework under this Act.

Requires the Director to consider each relevant scientific framework developed under this Act when making recommendations for exception funding for grant applications.

]]>

Recalcitrant Cancer Research Act of 2012 Short Titles as Introduced Recalcitrant Cancer Research Act of 2012 Short Titles as Reported to Senate Recalcitrant Cancer Research Act of 2012 S Senate Display Title Recalcitrant Cancer Research Act of 2012 Official Title as Introduced An original bill to provide for scientific frameworks with respect to recalcitrant cancers. Reported to Senate 2012-09-19T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-112s3566rs/xml/BILLS-112s3566rs.xml 2012-09-19 Placed on Senate Legislative Calendar under General Orders. Calendar No. 521. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.